# Sanqi oral solution alleviates podocyte apoptosis in experimental membranous nephropathy by mediating EMT through the ERK/CK2-α/β-catenin pathway

**Authors:** Xiaowan Wang, Juanjuan Wang, Bidan Zheng, Ruimin Tian, Lihua Huang, Wei Mao, Yi Feng, Bo Liu, Peng Xu

PMC · DOI: 10.3389/fphar.2025.1503961 · Frontiers in Pharmacology · 2025-05-09

## TL;DR

Sanqi oral solution reduces kidney damage in a rat model of membranous nephropathy by preventing podocyte death through a specific molecular pathway.

## Contribution

The study reveals that Sanqi oral solution inhibits podocyte apoptosis via the ERK/CK2-α/β-catenin pathway-mediated EMT in membranous nephropathy.

## Key findings

- SQ reduced proteinuria, MAC, and glomerular basement membrane thickness in PHN rats.
- SQ inhibited podocyte apoptosis and EMT markers like vimentin and α-SMA.
- SQ increased protective proteins Synaptopodin and Podocin in podocytes.

## Abstract

Sanqi oral solution (SQ) is a Chinese medicine that has been used well to treat idiopathic membranous nephropathy (IMN). It has been demonstrated to mitigate IMN proteinuria by inhibiting podocyte apoptosis. however, the precise mechanism has not been fully elucidated.

A passive Heymann nephropathy (PHN) rat model was used to mimic the in vivo disease characteristics of IMN. The PHN rats were intragastrically administered SQ (12.6/6.3 mL/kg) or tacrolimus (0.315 mg/kg) for 21 days. SQ was applied to ADR-induced podocytes in vitro. The effects of SQ on IMN and its underlying mechanisms were determined by measuring biochemical indices, pathomorphological characteristics, membrane attack complex (MAC), cell morphology, and protein levels.

The SQ ingredients found in rat serum underscored their successful absorption in rats. In PHN rats, SQ induced a significant reduction in proteinuria, MAC, C5b-9, and glomerular basement membrane thickness, along with a drop in apoptotic podocytes. Similarly, SQ exerted a protective effect against ADR-induced podocyte injury by inhibiting apoptosis. Furthermore, inhibition of the ERK/CK2-α/β-catenin pathway-mediated epithelial-to-mesenchymal transition (EMT) was found to be involved in the anti-apoptotic effect of SQ in PHN rats and podocytes, marked by the reduction in vimentin and α-SMA and the induction of Synaptopodin and Podocin protein levels.

Inhibition of EMT via the ERK/CK2-α/β-catenin pathway may be the main mechanism by which SQ suppresses podocyte apoptosis in IMN.

## Linked entities

- **Proteins:** EPHB2 (EPH receptor B2), ck2a (casein kinase 2 alpha subunit), ctnnb1.S (catenin beta 1 S homeolog), PRELID1 (PRELI domain containing 1), ACTA1 (actin alpha 1, skeletal muscle), Nphs2 (NPHS2 stomatin family member, podocin)
- **Chemicals:** tacrolimus (PubChem CID 445643), ADR (PubChem CID 31703)
- **Diseases:** idiopathic membranous nephropathy (MONDO:0013860), membranous nephropathy (MONDO:0005376)
- **Species:** Rattus norvegicus (taxon 10116), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** Vim (vimentin) [NCBI Gene 81818], Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, Synpo (synaptopodin) [NCBI Gene 60324], Nphs2 (NPHS2 stomatin family member, podocin) [NCBI Gene 170672] {aka podocin}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}
- **Diseases:** Heymann nephropathy (MESH:D015433), proteinuria (MESH:D011507)
- **Chemicals:** ADR (MESH:D004317), SQ (-), tacrolimus (MESH:D016559)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12098599/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12098599/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC12098599/full.md

---
Source: https://tomesphere.com/paper/PMC12098599